[an error occurred while processing this directive]

Planning & Management Nuggets

From Disaster Recovery Journal

Building a Comprehensive Disaster Recovery Plan
Linda Cerni explores the new world of BC planning in the wake of the 2005 disasters. Cerni says an effective disaster recovery plan addresses not only the protection and recovery of technology, but as part of a broader BCP, also includes the people, processes, and procedures necessary to bring about the true end game: the ability for end users to manage corporate risk, respond to a potential disruption, and complete new business transactions while protecting historical transactions that together keep a company viable when faced with a disaster event.

www.drj.com/articles/spr06/1902-12.html

When Private Plans Go Public
We hear a lot about plan security, but what about the “public” plan: A plan which meets client and regulator requirements but maintains the level of secrecy needed to protect the Company A’s of the world from prying eyes. John Glenn reports.

www.drj.com/articles/fall05

Bioterrorism: What Is It? What Can Be Done to Prepare?
The threat of a biological attack on the United States is real and serious, writes James Hammill. Federal, state, and local governments are grappling with how to best detect an attack, identify the biological agent(s), warn the public, and provide specific instructions regarding actions to be taken for protection. Many of the same best practices that apply to response to bio-terrorism attacks should be applied to other wide-scale disasters when the private sector must work with the government agencies that take charge.

www.drj.com/articles/win06/1901-01.html

From CIO.com

Cleaning Up After Katrina
Tom Oreck, the CEO of Oreck Corp. credits quick thinking by employees (including his VP of IT) for a speedy recovery from the hurricane. After all, the systems don't run themselves. Stephanie Overby reports.

www.cio.com/archive/031506/view_oreck.html

Rx for Risk
As it revamps its workflow processes, the FDA is relying on technology to reduce the risk that unsafe substances—such as the pain reliever Vioxx—will get into the market. Allan Holmes explores the issue in-depth.

www.cio.com/archive/031506/fda.html

 
[an error occurred while processing this directive]